Phase I Study of Pyrotinib in Patients With HER2-positive Solid Tumors
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Gastric Cancer|Solid Tumors|NSCLC
Interventions: DRUG: Pyrotinib
Sponsor: Hengrui Therapeutics, Inc.